“Open-Label Extension and Safety Study of Talazoparib”
This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.
Drug - Talazoparib
Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
A SINGLE-ARM, OPEN-LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB